Aberdeen Group plc Purchases 202,297 Shares of Disc Medicine, Inc. $IRON

Aberdeen Group plc grew its stake in shares of Disc Medicine, Inc. (NASDAQ:IRON) by 631.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 234,358 shares of the company’s stock after buying an additional 202,297 shares during the period. Aberdeen Group plc owned 0.62% of Disc Medicine worth $18,610,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of IRON. Arizona State Retirement System boosted its holdings in Disc Medicine by 1.8% in the third quarter. Arizona State Retirement System now owns 6,654 shares of the company’s stock valued at $440,000 after acquiring an additional 120 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Disc Medicine by 2.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,094 shares of the company’s stock valued at $469,000 after acquiring an additional 138 shares during the period. Avanza Fonder AB lifted its holdings in Disc Medicine by 14.1% in the 4th quarter. Avanza Fonder AB now owns 1,903 shares of the company’s stock worth $151,000 after purchasing an additional 235 shares in the last quarter. HighVista Strategies LLC raised its holdings in shares of Disc Medicine by 4.3% during the 2nd quarter. HighVista Strategies LLC now owns 6,733 shares of the company’s stock worth $357,000 after acquiring an additional 275 shares in the last quarter. Finally, Alliancebernstein L.P. increased its position in shares of Disc Medicine by 1.7% during the 3rd quarter. Alliancebernstein L.P. now owns 24,540 shares of the company’s stock valued at $1,622,000 after purchasing an additional 400 shares during the last quarter. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Disc Medicine Stock Up 1.0%

Shares of NASDAQ IRON opened at $65.82 on Tuesday. The stock has a fifty day moving average price of $66.45 and a 200 day moving average price of $75.96. The company has a current ratio of 21.94, a quick ratio of 21.94 and a debt-to-equity ratio of 0.04. The company has a market cap of $2.51 billion, a P/E ratio of -10.99 and a beta of 0.91. Disc Medicine, Inc. has a 12-month low of $30.82 and a 12-month high of $99.50.

Disc Medicine (NASDAQ:IRON) last announced its earnings results on Thursday, February 26th. The company reported ($1.62) earnings per share for the quarter, beating the consensus estimate of ($1.69) by $0.07. The business had revenue of ($19.88) million for the quarter, compared to analyst estimates of $0.15 million. Research analysts anticipate that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on IRON shares. Stifel Nicolaus cut their price objective on Disc Medicine from $125.00 to $110.00 and set a “buy” rating on the stock in a research report on Tuesday, February 17th. Truist Financial dropped their price objective on Disc Medicine from $114.00 to $83.00 and set a “buy” rating on the stock in a report on Friday, February 27th. UBS Group reiterated an “overweight” rating on shares of Disc Medicine in a research report on Thursday, January 15th. TD Cowen reaffirmed a “buy” rating on shares of Disc Medicine in a research note on Friday, December 19th. Finally, Morgan Stanley set a $75.00 price objective on Disc Medicine in a research report on Tuesday, February 17th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $104.80.

Insider Activity

In other Disc Medicine news, CEO John D. Quisel sold 13,264 shares of Disc Medicine stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $62.86, for a total transaction of $833,775.04. Following the transaction, the chief executive officer directly owned 226,064 shares in the company, valued at approximately $14,210,383.04. The trade was a 5.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Jonathan Yen-Wen Yu sold 3,231 shares of Disc Medicine stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $62.86, for a total transaction of $203,100.66. Following the sale, the chief operating officer directly owned 54,324 shares of the company’s stock, valued at $3,414,806.64. This trade represents a 5.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 48,022 shares of company stock worth $3,068,494. 3.64% of the stock is owned by corporate insiders.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.